

OKLAHOMA HEALTH CARE AUTHORITY
REGULAR BOARD MEETING
September 16, 2026, at 2:00 P.M.
Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, OK. 73105

AGENDA

Public access via Zoom:

https://www.zoomgov.com/webinar/register/WN_gQ4mzMOsTAeocEDu0v62VQ

Telephone: 1-669-216-1590 Webinar ID: 161 686 4828

*Please note: Since the physical address for the OHCA Board Meeting has resumed, any livestreaming option provided is provided as a courtesy. Should such livestreaming option fail or have technical issues, the OHCA Board Meeting will not be suspended or reconvened because of this failure or technical issue.

1. Call to Order / Determination of Quorum.....Marc Nuttle, Chair
2. Public Comment.....Marc Nuttle, Chair
3. Discussion and Vote on the June 26, 2026, OHCA Board Meeting Minutes.....Marc Nuttle, Chair
4. Chief Executive Officer Report.....Aaron Morris, Interim Chief Executive Officer
 - a) Member Moment
5. State Medicaid Director Update (Attachment “A”).....Melissa Miller, State Medicaid Director
6. Discussion of Report from the Pharmacy.....Phillip Kennedy
Advisory Committee and Possible Action Regarding Pharmacy Advisory Committee
Drug Utilization Review Board Recommendation:
 - a) Discussion and Possible Vote on Recommendations Made by the Drug Utilization Review Board Pursuant to 63 O.S. § 5030.1, § 5030.3 To Add the Following Drugs to the Utilization and Scope Prior Authorization Program under OAC 317:30-5-77.2(e) (Attachment “B”):

Item:	Drug Name:	Used For:
i.	Inlexzo™ (Gemcitabine Intravesical System)	Bladder Cancer (BC)
	Kyxata™ (Carboplatin)	Ovarian Cancer (OC)
	Lifyorli™ (Relacorilant)	OC
	Zusduri™ (Mitomycin Intravesical Solution)	BC
ii.	Nereus™ (Tradipitant)	Motion Sickness
	Posfrea™ (Palonosetron Injection)	Nausea and vomiting associated with chemotherapy and post-surgery
iii.	Hepcludex® (Bulevirtide-gmod)	Hepatitis D (HD)
	Relenza® (Zanamivir Inhalation Powder)	Influenza (flu)
	Xofluza® (Baloxavir)	flu
iv.	Loargys® (Pegzilarginase-nbln)	Arginase 1 Deficiency (ARG1-D)
v.	Various Special Formulations: Averi™ (Desogestrel/Ethinyl Estradiol/Ferrous Bisglycinate)	Contraceptive

Desmoda™ (Desmopressin Oral Solution)	Central Diabetes Insipidous (CDI)
Dicyclomine 40mg Tablet	Irritable Bowel Syndrome
Griseofulvin Ultramicrosize 165mg Tablet	Ringworm
Hydroxyzine Oral Solution Unit Dose Cups (UDCs)	Anxiety Disorder (AD)
Khindivi™ (Hydrocortisone Oral Solution)	Primary Adrenal Insufficiency (PAI)
PoKonza™ (Potassium Chloride Oral Solution)	Hypokalemia
PoKonza™ (Potassium Chloride 15mEq Packet)	Hypokalemia
Potassium Chloride 40mEq Packet	Hypokalemia
Quiofic™ (Folic Acid Oral Solution)	Megaloblastic Anemia (MA)
Relgaabi™ (Gabapentin 200mg Capsule)	Postherpetic Neuralgia (PN)
Vykoura™ (Leucovorin Injection)	MA

7. Discussion of Report from the.....Phillip Kennedy
Compliance Advisory Committee Chair, Compliance Advisory Committee
and Possible Action
 - a) Discussion and Possible Vote to Approve the State Plan Amendment Rate Committee Rates pursuant to 63 O.S. Section 5006 (A)(2) under OAC 317:1-3-4 (Attachment “C”)
 - i. Assisted Living Tiered Rate Increase
8. Discussion of Report from the.....Kevin Corbett
Managed Care Oversight Committee Chair, Managed Care Oversight Committee
9. Discussion of Report of the Administrative.....Tanya Case
Rules Advisory Committee and Possible Action Chair, Administrative Rules Advisory Committee
(Attachment “D”)
 - i. APA WF # 26-04 HR1 Reduced Retroactive Eligibility and 6-Month Redetermination
 - ii. APA WF # 26-06 HR1 Work Requirements
 - iii. APA WF # 26-12 Obstetrical Unbundling
10. Discussion of Report of Strategic.....Marc Nuttle, Chair
Planning & Operational Advisory Committee Chair, Strategic Planning & Operational Advisory Committee
 - a) Discussion and Possible Vote Regarding a Strategic Stakeholder Meeting
11. Adjournment.....Marc Nuttle, Chair

NEXT BOARD MEETING
 December 9, 2026, at 2:00PM
 Oklahoma Health Care Authority
 4345 N. Lincoln Blvd
 Oklahoma City, OK 73105